LLYNYSEChecked

What is Eli Lilly tied to?

Eli Lilly makes Mounjaro for diabetes and Zepbound for weight loss, two brand names for the same medicine, tirzepatide. Together they brought in $16.1 billion of Lilly's $24.4 billion of revenue in the third quarter of 2026. In April 2026 it added Foundayo, a weight-loss pill.

Biggest ties: Chugai Pharmaceutical (discovered its weight-loss pill); Amazon Pharmacy (delivers LillyDirect orders); Drug wholesalers (McKesson, Cencora, Cardinal Health)

The map

Suppliers sit above Eli Lilly, customers below. Tap a box, or step through with the arrows.

Lilly depends on1 of 8

Chugai Pharmaceutical

Size$184 million of Foundayo sales (Q3 2026)

Orforglipron, sold as Foundayo since April 2026, was discovered by Chugai, a Japanese drugmaker. Lilly develops and sells it.

What to watch: Foundayo sales, which reached $184 million in the third quarter of 2026, up from $98 million.

Boxes with a corner arrow have their own map. Sizes show where a source gives one.

Outside forces

Things Eli Lilly can't control that affect its business. Tap one to see what to watch.

Weight-loss demandWorldwide sales volume rose 53% in the third quarter of 2026 while prices fell 15%. Lilly raised its 2026 revenue forecast to $91 billion to $92 billion.What to watch

Whether volume keeps outrunning price cuts.

Sources: Lilly: third-quarter 2026 results; Earnings Whispers: Lilly Q3 2026 releaseChecked

Lower US pricesUS prices fell 7% in the quarter, mostly on Zepbound. The White House deal set lower prices for Medicare, Medicaid and the TrumpRx website.What to watch

Further price cuts as more people are covered.

Sources: Lilly: third-quarter 2026 results; Healthcare Dive: Lilly, Novo strike obesity drug pricing deal; Becker's: Medicare to cover GLP-1s under negotiated pricingChecked

Pill race with NovoNovo Nordisk launched a Wegovy pill in January 2026. Lilly's Foundayo followed in April and can be taken without food or water limits.What to watch

Which pill doctors and insurers favor.

Sources: Zacks: Lilly Q3 2026 results; Lilly: FDA approves Foundayo (orforglipron)Checked

Latest earnings

Q3 2026, quarter to Sep 30, 2026

Reported Oct 29, 2026Next report date not announced yet

Revenue

$24.40B

Up 39% from $17.60B a year earlier

Earnings per share

$7.22

Up 16% from $6.21 a year earlier

Includes $4.57 a share of charges for buying drugs in development, mainly from the AtaiBeckley and Curevo deals.

Sales, last four quartersIn billions of dollars. The last bar is the quarter above.
  1. $19.29BOct–Dec
    2025
  2. $19.80BJan–Mar
    2026
  3. $22.97BApr–Jun
    2026
  4. $24.40BJul–Sep
    2026

Source: Stock Analysis: LLY quarterly income statementChecked

Company outlook: Lilly expects 2026 revenue of $91.0 billion to $92.0 billion, up from $85 billion to $87 billion.

Ties to the map: Mounjaro and Zepbound, sold through the wholesalers and partners on the map, made up about two thirds of revenue.

Compared with the same quarter a year earlier, as reported by the company.

Sources: Lilly: third-quarter 2026 results; Lilly: third-quarter 2026 results (SEC)

Where the money comes from

Share of Eli Lilly's sales by business and region. Third quarter of 2026, as reported by the company.

By business

  • Mounjaro44%$10.72B
  • Zepbound22%$5.35B
  • Other medicines34%$8.32B

By region

  • United States62%$15.10B
  • Outside the US38%$9.30B

Other medicines include newer drugs such as Jaypirca, Ebglyss, Kisunla and Foundayo, plus $410 million of Jardiance milestones.

Source: Lilly: third-quarter 2026 resultsChecked

Competes with

Novo NordiskOzempic, Wegovy and the Wegovy pill
MerckLarge drugmakerOpen mapAbbVieImmunology and cancer drugsOpen map

More in Drugmakers

Common questions

Are Mounjaro and Zepbound the same drug?

Yes. Both are tirzepatide. Mounjaro is approved for type 2 diabetes and Zepbound for weight loss.

What is Foundayo?

Lilly's weight-loss pill, orforglipron, approved by the FDA on April 1, 2026. It was discovered by Chugai and can be taken any time of day without food or water limits.

Who does Lilly sell its medicines to?

Mostly to drug wholesalers. Its three largest, McKesson, Cencora and Cardinal Health, were each 16% to 24% of 2025 revenue. It also sells directly to patients through LillyDirect.

Read every connection

All 8 connections as cards, with sources. It's the same detail you get by tapping a box on the map.
Show allHide

Suppliers

The companies Eli Lilly relies on to make what it sells, with sources.

Chugai Pharmaceutical

Discovered its weight-loss pill

Size$184 million of Foundayo sales (Q3 2026)

Orforglipron, sold as Foundayo since April 2026, was discovered by Chugai, a Japanese drugmaker. Lilly develops and sells it.

What to watch: Foundayo sales, which reached $184 million in the third quarter of 2026, up from $98 million.

Sources: Lilly: FDA approves Foundayo (orforglipron); Zacks: Lilly Q3 2026 resultsChecked

Customers

Who buys from Eli Lilly or pays it, with sources.

Drug wholesalers

McKesson, Cencora, Cardinal Health

SizeEach 16% to 24% of 2025 revenue

Most of Lilly's medicines are sold to wholesalers that supply pharmacies and hospitals. In 2025 its three largest, McKesson, Cencora and Cardinal Health, were each 16% to 24% of revenue.

What to watch: Rebates and discounts, which lower what Lilly keeps from each sale.

Sources: Lilly 10-K for 2025, revenue note (via edgar.tools); Autobound: Lilly 10-K summaryChecked

Hims & Hers

Telehealth seller

Size not disclosed in our sources

Since November 6, 2026, patients on Hims & Hers can buy Zepbound and Foundayo directly at Lilly's self-pay prices, $299 and $149 a month to start. Lilly also works with Ro, WeightWatchers and GoodRx.

What to watch: Telehealth, which Lilly says is how 30% to 40% of patients get obesity medicines.

Sources: Pharmacy Times: Lilly and Hims & Hers GLP-1 deal; eMarketer: Hims joins Lilly's network of partnersChecked

Medicare and Medicaid

Government drug plans

Size not disclosed in our sources

Under a November 2025 deal with the White House, Medicare pays $245 a month for Zepbound and Mounjaro and covers them for obesity, with patients paying $50. State Medicaid programs can get the same price.

What to watch: How many seniors start treatment, and the lower price per patient.

Sources: Healthcare Dive: Lilly, Novo strike obesity drug pricing deal; Becker's: Medicare to cover GLP-1s under negotiated pricingChecked

Patients outside the US

International sales

Size$9.3 billion (Q3 2026)

Revenue outside the US rose 47% to $9.3 billion in the third quarter of 2026. Mounjaro sold $5.7 billion outside the US, more than inside it.

What to watch: Prices abroad, which fell as volume rose.

Source: Lilly: third-quarter 2026 resultsChecked

About this page

Connections were last checked against company filings and news reports on Nov 21, 2026. Companies don't have to disclose every supplier or customer, so this map shows the most important ones that are publicly known, not every link.

How we check connections. StockTies is for information only. It is not investment advice. Spot something out of date? Tell us.